

HYDROPHILIC POLYMERS FOR DISSOLUTION ENHANCEMENT OF CELECOXIB

PROF.M.V.NAGABHUSHANAM^{1*}, CH.V.PRASADA RAO², CH.PRABHAKAR³,^{*1} DCRM Pharmacy College, Inkollu, Prakasam (Dt.), A.P. 523167, ² Vishwa Bharathi College of Pharmaceutical Sciences, Perecherla, Guntur, ³ Chilukuri Balaji Pharmacy College, Aziz Nagar, Hyderabad India. Email: priya_narendra@rediffmail.com

Received: 29 July 2011, Revised and Accepted: 21 Aug 2011

ABSTRACT

Solid Dispersions of celecoxib (C), with water soluble polymers poly vinyl pyrrolidone (PVP), poly ethylene glycol (PEG), hydroxyl propyl methyl cellulose (HPMC) were prepared by solvent evaporation methods employing methanol as solvent. Solid Dispersions prepared were evaluated for dissolution rate and dissolution efficiency in comparison to the corresponding pure drug. Solid dispersions of celecoxib showed a marked enhancement in dissolution rate and dissolution efficiency. Solid dispersions at 8:2 ratios of C: HPMC a 3.28 fold increase in the dissolution rate of celecoxib was observed. Solid dispersions with hydrophilic polymers could be used to enhance the dissolution rate of poorly soluble drug celecoxib.

Keywords: Celecoxib, Solid Dispersions, Dissolution rate, Solubility, hydrophilic polymer.

INTRODUCTION

Celecoxib (C), 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benzene sulfonamide, is a nonsteroidal anti-inflammatory drug that exhibits anti-inflammatory, analgesic and anti-pyretic activities is used in the treatment of rheumatoid arthritis and osteoarthritis^(1,2). Celecoxib is also used in the management of acute pain and dysmenorrhoea, as an adjunct to standard therapy⁽³⁾ to reduce the number of adenomatous colorectal polyps in patients with familial adenomatous polyposis. The mechanism of action of celecoxib is believed to be due to inhibition of prostaglandin synthesis, primarily via inhibition of cyclooxygenase-2 (COX-2) and at therapeutic concentrations in humans, celecoxib does not inhibit the cyclooxygenase-1 (COX-1) isoenzyme. Celecoxib is absorbed slowly from the gastrointestinal tract, peak plasma concentrations⁽⁴⁾ being achieved approximately 4hrs after an oral dose. Most of the NSAIDs belong to class II category under Biopharmaceutical classification system (BCS) i.e., they are inherently highly permeable through biological membranes, but exhibit low aqueous solubility. Rate of absorption and / or extent of bioavailability for such insoluble hydrophobic drug is controlled by rate of dissolution in gastro-intestinal fluids⁽⁵⁾. The present study aims at enhancing the dissolution rate of celecoxib. In the present investigation solid dispersions⁽⁶⁾ were prepared by employing common solvent and solvent evaporation methods. Studies were carried out on celecoxib with an objective of enhancing their dissolution rates and bioavailability. Water dispersible super disintegrant DCP, a new class of tablet excipient was evaluated as carrier, alone and in combination with PVP, HPMC, PEG for enhancing the dissolution rate and bioavailability of celecoxib. Deposition of drug on the surface of an inert carrier leads to reduction in the particle size of the drug, thereby providing faster rate of distribution⁽¹⁰⁾. One of the methods of increasing bio availability is by using inclusion complex⁽¹¹⁾

MATERIALS AND METHODS

Celecoxib was a gift sample from M/s. Sigma Laboratories, Mumbai, methanol (Qualigens) and polyvinyl pyrrolidone (PVP K₃₀) was a gift sample from M/s. Sun Pharma Ind. Ltd., Mumbai. All other materials used were of pharmacopoeial grade and were procured from commercial sources.

Preparation of Solid Dispersions Employing Hydrophilic Polymers

The required quantities of C and water soluble carriers (PEG, PVP, HPMC) were dissolved in the solvent to get a clear solution in a dry mortar. The solvent was then evaporated by continuous trituration. Trituration was continued until a dry mass was obtained. The mass obtained was further dried at 50° C for 4 hours in an oven. The product was crushed, pulverized and shifted through mesh N0.100.

Various solid dispersions prepared with their composition are listed in Table 1.

Table 1: Composition of various solid dispersions prepared

S. No	Drug	Carriers	SD Code
1.	Celecoxib (8)	PEG(2)	C-PEG 82
2.	Celecoxib (8)	PVP(2)	C-PVP 82
3.	Celecoxib (8)	HPMC(2)	C-HPMC 82

Estimation of Celecoxib

A spectrophotometric method based on the measurement of absorbance at 254 nm in water containing 1% SLS was used in the present study for the estimation of celecoxib⁽⁷⁾. The method was validated for reproducibility, accuracy, precision and linearity by analyzing six individually weighed samples of celecoxib. The stock solution of celecoxib was subsequently diluted to a series of dilution containing 5, 10, 15 and 20 µg/ml of solution, using water containing 1% SLS. The absorbance of these solutions was measured in UV-VIS spectrophotometer (ELICO SL-159). The method obeyed Beer's law in the concentration of 0-20 µg/ml.

Estimation of Celecoxib Solid Dispersions Prepared

From each batch, 4 samples of 50 mg each were taken and analyzed for the drug celecoxib. 50 mg of dispersions were weighed into a 100 ml volumetric flask. Methanol was added and mixed the contents thoroughly to dissolve the drug from the dispersion. The solution was then filtered and collected carefully into another 100 ml volumetric flask. The solution was made up to volume with the solvent. The solution was suitably diluted with 1% SLS and assayed at 254 nm for celecoxib. The results are given in Table 2.

Dissolution Rate Studies on Solid Dispersions

Dissolution rate of celecoxib were studied using an USP XXIII six station dissolution rate test apparatus (Electro Lab). Paddle stirrer at a speed of 50 rpm and temperature of 37° ± 1°C were used in each test. Drug or solid dispersion of drug equivalent to 100 mg of celecoxib was used in each dissolution rate test. Samples of dissolution medium i.e., water containing 1% SLS (5ml) were withdrawn through a filter (0.45 µ) at different time intervals, suitably diluted, and assayed for celecoxib. The dissolution experiments were conducted in triplicate. The results are given in Table 3. Dissolution rates of celecoxib and its solid dispersions followed first order kinetics (Table 4). Dissolution parameters such as T₅₀, DE₃₀, K₁, Percent of celecoxib dissolved in 10 minutes are given in Table 5.

Table 2: Celecoxib Content of Various Solid Dispersions Prepared

S No.	SD Code	Percent Celecoxib Content ($\bar{x} \pm s.d.$)
1.	C-PEG	79.98 \pm 0.52 (0.79)
2.	C-PVP	79.89 \pm 0.57 (0.75)

Table 3: Dissolution Profiles of Celecoxib Solid Dispersions

Time (min.)	Percent Celecoxib Dissolved ($\bar{x} \pm s.d.$, n = 3)			
	C	C-PEG 82	C-PVP 82	C-HPMC 82
5	24.42 \pm 0.63	26.7 \pm 1.41	37.2 \pm 0.66	31.6 \pm 0.48
10	30.37 \pm 0.38	33.9 \pm 1.52	43.0 \pm 1.82	46.5 \pm 1.66
20	33.86 \pm 0.56	39.3 \pm 1.87	45.9 \pm 0.11	52.2 \pm 0.25
30	35.13 \pm 0.69	41.5 \pm 1.54	50.4 \pm 2.22	53.6 \pm 0.32
45	37.83 \pm 0.71	43.5 \pm 1.23	53.2 \pm 0.13	59.3 \pm 0.48
60	39.41 \pm 0.54	48.5 \pm 0.69	57.1 \pm 2.06	68.4 \pm 2.75
90	42.66 \pm 0.98	54.7 \pm 0.87	67.9 \pm 1.95	77.7 \pm 0.87
120	45.75 \pm 0.98	57.8 \pm 0.27	68.3 \pm 1.87	78.8 \pm 0.63

Table 4: The Correlation Coefficient (r) values in the Analysis of Dissolution Data of Celecoxib Solid Dispersions as per Zero order, First Order and Hixson-Crowell Cube Root Models

S. No.	Solid Dispersion	Correlation Coefficient (r) Value		
		Zero order	First order	Hixson-Crowell
1.	Celecoxib	0.9435	0.9536	0.99
2.	C-PEG	0.806	0.887	0.967
3.	C-PVP	0.783	0.889	0.974
4.	C-HPMC	0.827	0.937	0.960




Fig. 1: Dissolution Profiles of Celecoxib and its solid dispersions

Table 5: Dissolution Parameters of Celecoxib and its Solid Dispersions in Super disintegrants

S. No.	Solid Dispersion	Dissolution Parameter			No. of folds increase in K_1
		T_{50} (min)	DE ₃₀ (%)	K_1 (min ⁻¹)	
1.	Celecoxib	>120	28.8	0.0035	-----
2.	C-PEG 82	65	32.94	0.0056	1.6
3.	C-PVP 82	29	40.65	0.0076	2.17
4.	C-HPMC 82	15	40.72	0.0115	3.28




Fig. 2: First Order Dissolution Plots of Celecoxib and its Solid Dispersions




Fig. 3: Hixson-Crowell Dissolution Plots of Celecoxib and its Solid Dispersions

Analysis of Dissolution Data of Solid Dispersions as per Hixson-Crowell's cube root law

The dissolution data of celecoxib and their solid dispersions were also analyzed as per Hixson-Crowell's⁽⁹⁾ cube root equation. Hixson-Crowell introduced the concept of changing surface area during dissolution and derived the "cube-root law" to nullify the effect of changing surface area and to linearize the dissolution curves. Hixson-Crowell's cube root law is given by the following equation. $(W_0)^{1/3} - (W_t)^{1/3} = Kt$, where W_0 is initial mass and W_t is the mass remained at time 't'. The cube root equation is applicable to the dissolution of monodisperse powder consisting of uniform sized particles. A plot of $(W_0)^{1/3} - (W_t)^{1/3}$ versus time will be linear when dissolution occurs from monodisperse particles of uniform size. Hixson-Crowell plots of the dissolution data were found to be linear (Fig.3) with all solid dispersions. This observation indicated the drug dissolution from all the solid dispersions is occurring from discretely suspended or deposited (monodisperse) particles. This might have also contributed to the enhanced dissolution rate of the solid dispersions. The correlation coefficient (r) values of the first order release model are found to be (0.887 to 0.937) slightly higher when compared to the Hixson-Crowell's cube root model. Hence the release of drug from the preparations followed predominantly first order kinetics compared to Hixson-Crowell cube root law. Correlation coefficient values in the analysis of dissolution data as per zero order, first order and Hixson-Crowell cube root are given in Table.3. Another parameter suitable for evaluation of *in vitro* dissolution has been suggested by Khan⁽⁹⁾ by a parameter Dissolution efficiency (DE). DE is defined as the area under the

dissolution curve up to a certain time 't' expressed as percentage of the area of the rectangle described by 100% dissolution in the same time.

$$\text{Dissolution Efficiency (DE)} = \left[\frac{\int_0^t y \cdot dt}{y_{100} \cdot t} \right] 100$$

The index DE₃₀ would relate to the dissolution of drug from a particular formulation after 30 minutes and could be compared with DE₃₀ of other formulations. Summation of the large dissolution data into a single figure DE enables ready comparison to be made between a large numbers of formulations.

RESULTS AND DISCUSSION

All the dissolution parameters given in Table 2 indicated rapid and higher dissolution of celecoxib from all solid dispersions when compared to celecoxib pure drug. Celecoxib-HPMC (8 :2) solid dispersion gave rapid and higher dissolution than the pure drug. A 3.28 fold increase in the dissolution rate of celecoxib was obtained with this solid dispersion when compared to pure drug. Combined carriers gave much higher enhancement in the dissolution rate of celecoxib than water dispersible carriers alone. Solid dispersions of superdisintegrants gave rapid and higher dissolution of celecoxib when compared to pure drug as well as its solid dispersion in water soluble PVP. In each case, the K₁ and DE₃₀ values were increased. A 3.28 fold increase in the dissolution rate of celecoxib was observed with celecoxib-HPMC-DCP solid dispersion. All the solid dispersions in combined carriers gave much higher rates of dissolution, several times higher than the dissolution rate of pure drug. MA-HPMC solid dispersion gave a 3.28 fold increase in the dissolution rate of

celecoxib. Thus water soluble carrier HPMC resulted in a greater enhancement in the dissolution rate of celecoxib.

CONCLUSION

Thus superdisintegrant DCP was found to be useful as a carrier in celecoxib solid dispersions alone and in combination with HPMC to enhance the solubility, dissolution rate and dissolution efficiency.

ACKNOWLEDGEMENT

The authors would like to express sincere thanks to the Management of D.C.R.M. Pharmacy College for their encouragement and providing necessary facilities in carryout this research work. The authors would also express sincere thanks to M/s. Sigma Laboratories, Mumbai for generous gift of celecoxib samples.

REFERENCES

1. Clemett, D., Goa, K.L., Drugs, 59, 957, 2000.
2. Bensen, W.G. et al., Mayo Clin. Proc., 74, 1095, 1999.
3. Steinbach G., et al., N.Engl. J. Med., 342, 1946, 2000.
4. Davies, N.M. et al., Clin. Pharmacokinet., 38, 225, 2000.
5. Guirguis M and Jammali F. J Pharm Pharmaceut Sci. 2001. 4: 77.
6. Sekiguchi K and Obi N, Chem Pharm Bull. 1961 9:866.
7. Teresa H, Ado, Jan Pawlaczyk. J of Inclusion Phenomena and Macrocyclic Chemistry, 1999, 3:35.
8. Hixon A.W. and Crowell J.H. Ind Eng Chem. 1931, 23:923.
9. Khan K.A, Rhodes C.T., Pharma Acta Helv. 1972, 47:594.
10. Punitha S, Vedha Hari BN, Karthikeyan D- Enhancement of Celecoxib solubility by solid dispersion using Mannitol: Int.JPPS: 2010: 2(4): 109-111
11. Deepthi Mathew: A study on suitability of Nimesulide-Beta Cyclo dextrin-Complex in oral and Topical Dosage forms. Int JPPS: 2009: 1(1): 193-198.